Neurolign

Apr 19 2022

The 20 Under 40 in Biopharma [Endpoint News]

https://www.neurolign.com/wp-content/uploads/2022/04/EPNThe-201-under-40-Your-guide-to-the-next-generation-of-biotech-leaders-–-Endpoints-News-1.pdf

Apr 18 2022

Love0

Kate Therapeutics Announces Closing of $50M Series A Financing to Advance AAV-based GeneTherapies

By Neurolign Press Release

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed non tincidunt leo, in porta metus. Nulla facilisi. Mauris at facilisis felis. Aliquam erat volutpat. Ut a bibendum turpis. Duis blandit…

Mar 24 2022

Love0

A Boost for Muscle with Gene Therapy [NEJM]

https://www.nejm.org/doi/10.1056/NEJMcibr2118576?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

The 20 Under 40 in Biopharma [Endpoint News]

Kate Therapeutics Announces Closing of $50M Series A Financing to Advance AAV-based GeneTherapies

A Boost for Muscle with Gene Therapy [NEJM]

Our Address

Contact Us